Daily Medication Pearl: Upadacitinib (Rinvoq)
Medication Pearl of the Day: Upadacitinib (Rinvoq)
Indication: Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.
- Dosing: The recommended dosage of Rinvoq is 15 mg once daily.
- Dosage forms: Extended-release tablets 15 mg and 30 mg.
- Adverse events: Adverse reactions (≥ 1%) were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, and acne.
- Mechanism of action: JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
- Manufacturer: AbbVie